Abacus FCF Advisors LLC Buys 6,931 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Abacus FCF Advisors LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 72.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,459 shares of the company's stock after purchasing an additional 6,931 shares during the period. Abacus FCF Advisors LLC owned approximately 0.05% of Medpace worth $5,015,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Lindbrook Capital LLC grew its stake in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares in the last quarter. HBK Sorce Advisory LLC increased its position in shares of Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. raised its stake in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after buying an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. boosted its stake in Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after buying an additional 30 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Mizuho decreased their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Finally, Robert W. Baird cut their price objective on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $349.30.

Medpace Stock Performance

NASDAQ:MEDP traded up $2.05 during trading hours on Thursday, hitting $304.36. 296,073 shares of the company's stock traded hands, compared to its average volume of 360,170. The stock's fifty day moving average price is $298.15 and its two-hundred day moving average price is $323.26. The firm has a market cap of $8.75 billion, a P/E ratio of 24.10, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the prior year, the firm earned $3.20 earnings per share. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Transactions at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.30% of the stock is currently owned by company insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.